XML 59 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Parent-Only Financial Statements (Tables) - Parent [Member]
12 Months Ended
Dec. 31, 2023
Parent-Only Financial Statements (Tables) [Line Items]  
Schedule of Condensed Balance Sheets
 

As of December 31,

   

2022

 

2023

   

RMB

 

RMB

 

US$

ASSETS/(LIABILITIES)

   

 

   

 

   

 

Cash and cash equivalents

 

25,769

 

 

1,205,993

 

 

170,273

 

Prepayments

 

 

 

13,776

 

 

1,945

 

Due from intercompany

 

380,321,338

 

 

456,041,568

 

 

64,388,096

 

Investment in subsidiaries

 

(215,932,707

)

 

(471,994,335

)

 

(66,640,453

)

TOTAL ASSETS (LIABILITIES)

 

164,414,400

 

 

(14,732,998

)

 

(2,080,139

)

SHAREHOLDERS’ EQUITY (DEFICIT)

   

 

   

 

   

 

Shareholders’ equity (deficit):

   

 

   

 

   

 

Class A ordinary shares ($0.0002 par value; 121,410,923 shares authorized; 27,159,258 and 41,927,302 shares issued as of December 31, 2022 and 2023, respectively; 27,159,258 and 37,242,359 shares outstanding as of December 31, 2022 and 2023, respectively)*

 

35,425

 

 

50,106

 

 

7,074

 

Class B ordinary shares ($0.0002 par value; 28,589,078 shares authorized; 28,589,078 shares issued and outstanding as of December 31, 2022 and 2023)*

 

36,894

 

 

36,894

 

 

5,209

 

Additional paid-in capital

 

354,803,564

 

 

428,310,028

 

 

60,472,705

 

Accumulated deficit

 

(199,207,921

)

 

(452,031,693

)

 

(63,821,945

)

Statutory reserves

 

6,647,109

 

 

6,647,109

 

 

938,499

 

Accumulated other comprehensive income

 

2,099,329

 

 

2,254,558

 

 

318,319

 

TOTAL NANO LABS LTD SHAREHOLDERS’ EQUITY (DEFICIT)

 

164,414,400

 

 

(14,732,998

)

 

(2,080,139

)

*        After giving effect of the reverse stock split, see Note 1.

Schedule of Condensed Statements of Operations and Comprehensive Income (Loss)
 

For the years ended December 31,

   

2021

 

2022

 

2023

   

RMB

 

RMB

 

RMB

 

US$

Net revenues

 

 

 

 

 

 

 

 

Operating expenses:

   

 

   

 

   

 

   

 

Selling and marketing expenses

 

980

 

 

 

 

 

 

 

General and administrative expenses

 

306,775

 

 

5,822,906

 

 

471,664

 

 

66,594

 

Total operating expenses

 

307,755

 

 

5,822,906

 

 

471,664

 

 

66,594

 

Loss from operations

 

(307,755

)

 

(5,822,906

)

 

(471,664

)

 

(66,594

)

Finance income

 

 

 

66,144

 

 

110,971

 

 

15,668

 

Investment income

 

 

 

53,809

 

 

 

 

 

Income (loss) from investment in subsidiaries

 

(174,636,729

)

 

36,821,839

 

 

(252,463,079

)

 

(35,645,033

)

Net income (loss) attributable to Nano Labs Ltd

 

(174,944,484

)

 

31,118,886

 

 

(252,823,772

)

 

(35,695,959

)

Comprehensive income (loss):

   

 

   

 

   

 

   

 

Net income (loss)

 

(174,944,484

)

 

31,118,886

 

 

(252,823,772

)

 

(35,695,959

)

Other comprehensive income (loss)

   

 

   

 

   

 

   

 

Foreign currency translation adjustment

 

(2,467,327

)

 

4,566,656

 

 

155,229

 

 

21,917

 

Total comprehensive income (loss) attributable to Nano Labs Ltd

 

(177,411,811

)

 

35,685,542

 

 

(252,668,543

)

 

(35,674,042

)

Schedule of Condensed Statements of Cash Flows
 

For the years ended December 31,

   

2021

 

2022

 

2023

   

RMB

 

RMB

 

RMB

 

US$

Net cash provided by (used in) operating activities

 

(535,017

)

 

3,911,561

 

 

344,012

 

 

48,571

 

Net cash used in investing activities

 

(201,554,446

)

 

(155,900,936

)

 

(68,918,960

)

 

(9,730,605

)

Net cash provided by financing activities

 

201,251,124

 

 

144,043,186

 

 

72,802,734

 

 

10,278,952

 

Effect of exchange rate changes on cash and cash equivalents

 

926,910

 

 

7,883,387

 

 

(3,047,562

)

 

(430,284

)

Net increase (decrease) in cash and cash equivalents

 

88,571

 

 

(62,802

)

 

1,180,224

 

 

166,634

 

Cash and cash equivalents at beginning of the year

 

 

 

88,571

 

 

25,769

 

 

3,639

 

Cash and cash equivalents at end of the year

 

88,571

 

 

25,769

 

 

1,205,993

 

 

170,273